FrauPharma

FrauPharma is an Italian biotechnology company dedicated to the research and development of novel small molecule therapeutics targeting neurodegenerative diseases and oncology. The company utilizes a proprietary discovery platform to design compounds that address complex disease mechanisms, such as neuroinflammation and protein misfolding. Its lead program, FP-01, is a clinical-stage candidate being evaluated for the treatment of Amyotrophic Lateral Sclerosis (ALS). FrauPharma operates with a lean R&D model, focusing on high-value assets and strategic collaborations to advance its pipeline toward clinical proof-of-concept. The company is headquartered in San Donato Milanese and maintains strong ties with academic research institutions in Italy.